Changes in Hong Kong stocks | Jietai Technology-P (07666) has risen more than 7% since the beginning of August, and has continued to rise by nearly 30%, leading the AI pharmaceutical sector for many consecutive days

The Zhitong Finance App learned that Jetai Technology-P (07666) has continued to be sought after for funding recently, leading the AI pharmaceutical sector for many consecutive days. Since the beginning of August, the cumulative increase has been close to 30%. As of press release, it rose 6.25% to HK$12.75, with a turnover of HK$17.3822 million.

According to the news, Hang Seng Index may announce the semi-annual index adjustment results on August 25, 2026. All changes will be implemented after the market closes on September 4 and will take effect on September 7. Guohai Pharmaceutical's team anticipates that Jetai Technology will soon be introduced. The bank pointed out that with 30e+ cash on hand, the platform side already bears its own profits and losses. After the pipeline data is read out, pipeline asset BD is expected to push the company into an era of full profit.

It is worth noting that the AI4S (AI for Science) field is a competitive focus of “future technology”, and AI4S ranked first in the “State Council's Opinions on Further Implementing “Artificial Intelligence +” Actions. Shen Wan Hongyuan released a research report saying that Jetai Technology's AI4S platform with nanomaterials and drug delivery as the core is essentially a “future technology” with high barriers and strong foresight. Its valuation logic should not be limited to the exact same historical target of the business, but should refer to the booming circuit where the market gave similar technical attributes during the same period.